I. Pioneer a new approach for drug target discovery that has implications for a broad range of developmental and chronic illnesses. II. Develop a robust technology platform for large-scale targeted genomic engineering to enable more complete recapitulation of human disease genotypes in animal models. We will enable precise introduction of combinations of disease-associated genetic mutations into a single animal model. III. Develop a technology for targeted epigenome modification to enable direct functional testing of causal links between specific epigenetic modifications and disease pathophysiology. IV. Identify fundamentally new classes of therapeutics for major depression.
Major depressive disorder is a devastating mental illness affecting millions of Americans annually, with a large fraction of patients unresponsive to available therapies. The proposed project aims to identify fundamentally new classes of therapeutics by probing the epigenetic mechanisms contributing to major depression, through a combination of innovative technology development, and systematically establishing causal links between epigenetic targets and disease phenotype. The technologies developed through this proposal will establish a new epigenetic paradigm for drug discovery and have broad impacts for many fields of biomedical research including cancer, diabetes, obesity, and other neurological disorders. THE FOLLOWING RESUME SECTIONS WERE PREPARED BY THE SCIENTIFIC REVIEW OFFICER TO SUMMARIZE THE OUTCOME OF DISCUSSIONS OF THE REVIEW COMMITTEE ON THE FOLLOWING ISSUES. COMMITTEE BUDGET RECOMMENDATIONS: The budget was recommended as requested.
| Nishimasu, Hiroshi; Shi, Xi; Ishiguro, Soh et al. (2018) Engineered CRISPR-Cas9 nuclease with expanded targeting space. Science 361:1259-1262 |
| Chow, Ryan D; Guzman, Christopher D; Wang, Guangchuan et al. (2017) AAV-mediated direct in vivo CRISPR screen identifies functional suppressors in glioblastoma. Nat Neurosci 20:1329-1341 |
| Gootenberg, Jonathan S; Abudayyeh, Omar O; Lee, Jeong Wook et al. (2017) Nucleic acid detection with CRISPR-Cas13a/C2c2. Science 356:438-442 |
| Smargon, Aaron A; Cox, David B T; Pyzocha, Neena K et al. (2017) Cas13b Is a Type VI-B CRISPR-Associated RNA-Guided RNase Differentially Regulated by Accessory Proteins Csx27 and Csx28. Mol Cell 65:618-630.e7 |
| Yan, Winston X; Mirzazadeh, Reza; Garnerone, Silvano et al. (2017) BLISS is a versatile and quantitative method for genome-wide profiling of DNA double-strand breaks. Nat Commun 8:15058 |
| Nishimasu, Hiroshi; Yamano, Takashi; Gao, Linyi et al. (2017) Structural Basis for the Altered PAM Recognition by Engineered CRISPR-Cpf1. Mol Cell 67:139-147.e2 |
| Shmakov, Sergey; Smargon, Aaron; Scott, David et al. (2017) Diversity and evolution of class 2 CRISPR-Cas systems. Nat Rev Microbiol 15:169-182 |
| Gao, Linyi; Cox, David B T; Yan, Winston X et al. (2017) Engineered Cpf1 variants with altered PAM specificities. Nat Biotechnol 35:789-792 |
| Platt, Randall J; Zhou, Yang; Slaymaker, Ian M et al. (2017) Chd8 Mutation Leads to Autistic-like Behaviors and Impaired Striatal Circuits. Cell Rep 19:335-350 |
| Joung, Julia; Konermann, Silvana; Gootenberg, Jonathan S et al. (2017) Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening. Nat Protoc 12:828-863 |
Showing the most recent 10 out of 70 publications
